Sunday 18 October 2026
Export COYA’s income statement to Excel — free account
Coya Therapeutics, Inc.
COYA Healthcare Biotechnology
Coya Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.9 million, up 123.6% from fiscal 2024. In the quarter to June 2026, revenue grew 49.0%, EPS grew 22.2% and free cash flow fell 27.8%, each against the same quarter a year earlier.
4.27
0.07
−1.61%
Follow COYA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (60.54%) | (51.31%) | (51.39%) | (62.18%) |
+8 more TTM periods Free account |
|
| (53.66%) | (46.09%) | (45.02%) | (54.54%) | ||
ROIC |
(15,230.92%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(49.76%) | (42.49%) | (48.16%) | (64.96%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.76) | (0.71) | (0.71) | (0.76) | |
Free Cash Flow |
(17.77) | (16.17) | (11.90) | (12.66) | |
Capital Expenditures |
(2.05) | (2.05) | (1.16) | (0.52) | |
| Other line items | |||||
Cash ROIC |
(20.56%) | (16.22%) | (13.25%) | (22.84%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
211.80% | 196.71% | 210.61% | 344.34% | |
Selling, General and Administrative Expense of Revenue |
147.96% | 157.67% | 144.09% | 258.73% | |
Share Based Compensation of Revenue |
66.27% | 68.09% | 53.99% | 99.73% | |
Operating CF/Net income |
0.73 | 0.67 | 0.51 | 0.66 | |
Depreciation/Fixed assets |
3.45 | 2.79 | 2.45 | 1.51 | |
Capex/Depreciation |
(106.28) | (87.59) | (42.50) | (18.83) | |
Revenue per Share |
0.34 | 0.35 | 0.47 | 0.24 | |
Operating CF per Share |
(0.67) | (0.62) | (0.64) | (0.73) | |
Capex per Share |
(0.09) | (0.09) | (0.07) | (0.03) | |
Capex to Sales |
0.26 | 0.26 | 0.15 | 0.13 |
Columns are period end dates